Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months

Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular ...

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< ...
Becker's ASC

CMS Suspends Automatic Denial of Institutional Claims Reporting Modifier -GA

CMS Suspends Automatic Denial of Institutional Claims Reporting Modifier -GA CMS has announced that Medicare contractors processing institutional claims should no longer automatically deny line items ...